| REVLIMID® (lenalidomide) | Official Site REVLIMID.com is a site for patients, caregivers and healthcare professionals to learn more about REVLIMID. Read More |
| Lenalidomide - Wikipedia, the free encyclopedia Lenalidomide (Revlimid), Celgene is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which ... Read More |
| Revlimid Information from Drugs.com Revlimid (lenalidomide) is used to treat anemia (a lack of red blood cells in the body) and multiple myeloma. Includes Revlimid side effects, interactions and ... Read More |
| Revlimid Official FDA information, side effects and uses. Accurate, FDA approved Revlimid information for healthcare professionals and patients - brought to you by Drugs.com. Read More |
| Revlimid - The Myeloma Beacon Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a ... Read More |
| Revlimid (Lenalidomide) Drug Information: Description, User ... Learn about the prescription medication Revlimid (Lenalidomide), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Read More |
| Revlimid, Lenalidomide, CC-5013 - Chemotherapy Drugs, Chemo Drug ... Revlimid is a trade name for the generic chemotherapy drug Lenalidomide. Revlimid is classified as an immunomodulatory agent and an antiangiogenic agent. Revlimid is ... Read More |
| Lenalidomide - PubMed Health - National Center for Biotechnology ... PubMed Health. A service of the National Library of Medicine, National ... Brand names. Revlimid Read More |
| What Is REVLIMID | REVLIMID® (lenalidomide) REVLIMID is used with dexamethasone to treat patients with multiple myeloma who have already had another treatment. Read More |
| CLL Topics: Revlimid to the Rescue? Revlimid to the Rescue? Date: January 30, 2007. by Chaya Venkat. Celgene Targets Revlimid as CLL Therapy . Other Articles on Revlimid: Harvey's Journal Entry ... Read More |
